IR@PKUHSC  > 北京大学医药卫生分析中心
学科主题公共卫生
Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using Y-90-Labeled Fully Human Antibody Panitumumab
Liu, Zhaofei1; Liu, Yan1; Jia, Bing1; Zhao, Huiyun1; Jin, Xiaona2; Li, Fang2; Chen, Xiaoyuan3; Wang, Fan1
刊名MOLECULAR CANCER THERAPEUTICS
2010-08-01
DOI10.1158/1535-7163.MCT-10-0444
9期:8页:2297-2308
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National Natural Science Foundation of China ; "863" project ; Ministry of Science and Technology of China ; NIH, National Institute of Biomedical Imaging and Bioengineering ; National Natural Science Foundation of China ; "863" project ; Ministry of Science and Technology of China ; NIH, National Institute of Biomedical Imaging and Bioengineering
研究领域[WOS]Oncology
关键词[WOS]SQUAMOUS-CELL CARCINOMA ; EGFR MONOCLONAL-ANTIBODY ; COLORECTAL-CANCER ; BREAST-CANCER ; INTEGRIN ALPHA(V)BETA(3) ; MDA-MB-435 CELLS ; PHASE-II ; IN-VITRO ; CETUXIMAB ; THERAPY
英文摘要

Panitumumab (ABX-EGF or Vectibix), the first fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), was approved by the Food and Drug Administration for treatment of patients with metastatic colorectal cancer. Here, we report for the first time the radioimmunotherapy (RIT) of EGFR-positive human head and neck cancer in a nude mouse model using pure beta(-) emitter Y-90-labeled panitumumab. Biodistribution and planar gamma-imaging studies were carried out with In-111-DOTA-panitumumab. The RIT efficacy of Y-90-DOTA-panitumumab was evaluated in UM-SCC-22B tumor model. CD31, Ki67, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling, and H&E staining were done on UM-SCC-22B tumor sections after treatment. The tumor uptake of In-111-DOTA-panitumumab in UM-SCC-22B tumor-bearing nude mice was 26.10 +/- 4.93, 59.11 +/- 7.22, 44.57 +/- 9.80, 40.38 +/- 7.76, and 14.86 +/- 7.23 % injected dose per gram of tissue at 4, 24, 72, 120, and 168 hours after injection, respectively. Immunotherapy with cold panitumumab (four doses of 10 mg/kg) did not cause significant antitumor effect. RIT with a single dose of 100 mu Ci 90Y-DOTA-panitumumab caused significant tumor growth delay and improved the survival in UM-SCC-22B tumor model. A single dose of 200 mu Ci Y-90-DOTA-panitumumab led to almost complete tumor regression (tumor volumes were 34.83 +/- 11.11 mm(3) and 56.02 +/- 39.95 mm(3) on days 0 and 46 after treatment, respectively). Histopathologic analysis of tumors and normal organs further validated the therapeutic efficacy and limited systemic toxicity of Y-90-DOTA-panitumumab. The high tumor uptake and prolonged tumor retention, as well as effective therapy, reveal that Y-90-DOTA-panitumumab may be a promising radioimmunotherapeutic agent to treat EGFR-positive solid tumors. Mol Cancer Ther; 9(8); 2297-308. (C) 2010 AACR.

语种英语
所属项目编号30870728 ; 20820102035 ; 30930030 ; 30900373 ; 2007AA02Z467 ; 2009ZX09103-733 ; 2009ZX09301-010 ; 2009ZX09103-746
资助者National Natural Science Foundation of China ; "863" project ; Ministry of Science and Technology of China ; NIH, National Institute of Biomedical Imaging and Bioengineering ; National Natural Science Foundation of China ; "863" project ; Ministry of Science and Technology of China ; NIH, National Institute of Biomedical Imaging and Bioengineering
WOS记录号WOS:000280734200014
引用统计
被引频次:22[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50369
专题北京大学医药卫生分析中心
作者单位1.Beijing Union Med Coll Hosp, Dept Nucl Med, Beijing, Peoples R China
2.Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China
3.Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD USA
推荐引用方式
GB/T 7714
Liu, Zhaofei,Liu, Yan,Jia, Bing,et al. Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using Y-90-Labeled Fully Human Antibody Panitumumab[J]. MOLECULAR CANCER THERAPEUTICS,2010,9(8):2297-2308.
APA Liu, Zhaofei.,Liu, Yan.,Jia, Bing.,Zhao, Huiyun.,Jin, Xiaona.,...&Wang, Fan.(2010).Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using Y-90-Labeled Fully Human Antibody Panitumumab.MOLECULAR CANCER THERAPEUTICS,9(8),2297-2308.
MLA Liu, Zhaofei,et al."Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using Y-90-Labeled Fully Human Antibody Panitumumab".MOLECULAR CANCER THERAPEUTICS 9.8(2010):2297-2308.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Zhaofei]的文章
[Liu, Yan]的文章
[Jia, Bing]的文章
百度学术
百度学术中相似的文章
[Liu, Zhaofei]的文章
[Liu, Yan]的文章
[Jia, Bing]的文章
必应学术
必应学术中相似的文章
[Liu, Zhaofei]的文章
[Liu, Yan]的文章
[Jia, Bing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。